Canadá - inglés - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 10mg - hydromorphone hydrochloride 10mg - opiate agonists

Canadá - inglés - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 100mg - hydromorphone hydrochloride 100mg - opiate agonists

Canadá - inglés - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 50mg - hydromorphone hydrochloride 50mg - opiate agonists

Canadá - inglés - Health Canada

sterinova inc. - hydromorphone hydrochloride - solution - 20mg - hydromorphone hydrochloride 20mg - opiate agonists

Canadá - inglés - Health Canada

sterinova inc. - hydromorphone hydrochloride - solution - 40mg - hydromorphone hydrochloride 40mg - opiate agonists

Estados Unidos - inglés - NLM (National Library of Medicine)

fresenius kabi usa, llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 1 mg in 1 ml - dilaudid injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve dilaudid injection for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid injection is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)]  - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.2)]  - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings and precautions (5.9)]  - hypersensitivity to hydr

Estados Unidos - inglés - NLM (National Library of Medicine)

mckesson rxpak inc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 4 mg - dilaudid oral solution and dilaudid tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve dilaudid oral solution and dilaudid tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expectedto be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid oral solution and dilaudid tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.6)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including

Estados Unidos - inglés - NLM (National Library of Medicine)

purdue pharma lp - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 5 mg in 5 ml - dilaudid oral solution and dilaudid tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve dilaudid oral solution and dilaudid tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expectedto be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid oral solution and dilaudid tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.6)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium citrate dihydrate; sodium chloride; citric acid; sodium hydroxide - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.